Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
about
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological SocietyRituximab in autoimmune diseasesReport on the 3rd Ottawa International Conference on Neuromuscular Biology, Disease and Therapy - September 24-26, 2015, Ottawa, Canada.Experience with long-term rituximab use in a multiple sclerosis clinicMechanisms of Autoantibody-Induced Pathology.Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.Myasthenia gravis: a clinical-immunological update.Rituximab therapy in pemphigus and other autoantibody-mediated diseases.Overcoming challenges in the diagnosis and treatment of myasthenia gravis.Myasthenia gravis: recent advances in immunopathology and therapy.Rituximab Restores IFN-γ-STAT1 Function and Ameliorates Disseminated Mycobacterium avium Infection in a Patient with Anti-Interferon-γ Autoantibody.Myasthenia gravis with antibodies to MuSK: an update.Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment.Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia.Clinical features and evolution of juvenile myasthenia gravis in a French cohort.A Novel Fusion Protein, AChR-Fc, Ameliorates Myasthenia Gravis by Neutralizing Antiacetylcholine Receptor Antibodies and Suppressing Acetylcholine Receptor-Reactive B Cells.Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis.Past, Present, and Future of Rituximab-The World's First Oncology Monoclonal Antibody Therapy.Rituximab Treatment in : Report of two paediatric cases
P2860
Q26765172-AB42A050-6C20-48D3-846C-C0372A2C1137Q28076091-B6CD6302-FA42-421F-8083-00712487A506Q30355125-3F85DE13-6F83-4EB6-9541-311EA84AA12DQ33692751-6554B93A-2F6A-4C9B-84EE-5FA900BCCC4AQ33740580-843EDD28-D05E-4DA4-AE4C-BD426BC21BE3Q36484465-AB3F633B-0FB1-4820-A656-091BA420A183Q36783864-4C6D4F4B-5C3E-4AAF-A789-5094396B2C0AQ37620483-8C3C1C5A-E924-4DD2-B4D4-2924B77C6E51Q38671442-1EE4A861-C03A-4E31-BA71-E99B78B435A4Q38969032-56C696F1-828A-4945-B754-0927C01A0EEAQ40044517-AF9ADA50-CC1E-445A-942B-E99365245FF8Q47674286-401E28FF-A18C-4095-B979-68BF97692702Q47837398-D3BB581D-A314-435A-BF62-8FDE1D6077F0Q48670922-6C31D483-25D9-4AAB-A3F0-6EE21906E7CAQ50213611-9FF16A9E-4665-4C76-B0A7-3B300F97EA9AQ51455621-F1111A7E-4AB2-42A3-B9E8-55E162E9F168Q55267717-C0450456-48BE-42D2-BBA3-8C7784FF47DEQ55283747-B3A557F8-5BCC-43AA-96DC-B9CF61ED6F47Q58757308-2C40DF5A-C3BA-4014-8A0C-77924E33A455
P2860
Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Efficacy and safety of rituxim ...... atic review and meta-analysis.
@en
type
label
Efficacy and safety of rituxim ...... atic review and meta-analysis.
@en
prefLabel
Efficacy and safety of rituxim ...... atic review and meta-analysis.
@en
P2093
P2860
P1433
P1476
Efficacy and safety of rituxim ...... atic review and meta-analysis.
@en
P2093
Amelia Evoli
Paolo Emilio Alboini
Valentina Damato
P2860
P2888
P304
P356
10.1007/S00415-014-7532-3
P577
2014-10-12T00:00:00Z
P6179
1043070053